| Literature DB >> 34249516 |
Huan Chen1, Jun Li2, Shanshan Yan3, Hui Sun4, Chuyi Tan4, Meidong Liu4, Ke Liu4, Huali Zhang4, Mingxiang Zou2, Xianzhong Xiao4.
Abstract
BACKGROUND: Early and accurate diagnosis of microorganism(s) is important to optimize antimicrobial therapy. Shotgun metagenomic sequencing technology, an unbiased and comprehensive method for pathogen identification, seems to potentially assist or even replace conventional microbiological methodology in the diagnosis of infectious diseases. However, evidence in clinical application of this platform is relatively limited.Entities:
Keywords: Antibiotic resistance; Culture; Infectious disease; Pathogen identification; Shotgun metagenomic sequencing
Year: 2021 PMID: 34249516 PMCID: PMC8253115 DOI: 10.7717/peerj.11699
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Study workflow.
(A) Schematic of comparative study workflow. Patients’ samples of body fluids were collected for conventional culture and 16S/ITS region PCR test. PCR-positive specimens which passed the quality control of sequencing were selected to perform shotgun metagenomic sequencing and bioinformatics analyses, and further comparative study between culture results and sequencing results. (B) Schematic of paired-end library construction in accordance with Illumina’s instruction. (C) Bioinformatics pipeline for shotgun metagenomic sequencing.
Figure 2Flowchart for enrollment.
Demographics of patients and sample characteristics.
| Variables ( | Value |
|---|---|
| Patient demographics | |
| Age (years), median ( | 57 (44–62) |
| Gender, Male, | 12 (60) |
| Days hospitalized, median ( | 17 (12–27) |
| Immunocompromised, | 6 (30) |
| Empirical antibiotics use before sampling, | 18 (90) |
| Temperature (°C), median ( | 38.5 (38–38.8) |
| WBC count (109/L), median ( | 15.4 (12.8–18.4) |
| Neutrophils (%), median ( | 89.15 (82.93–94.90) |
| Procalcitonin (ng/mL), median ( | 1.87 (0.49–55.92) |
| SOFA score, median (IQR) | 2 (0–5) |
| Sample features | |
| Sample type, | |
| Abscess | 5 (25) |
| Cerebrospinal fluid | 5 (25) |
| Bile | 4 (20) |
| Others | 6 (30) |
| Positive culture rate, | |
| Bacteria positive | 18 (90) |
| Fungi positive | 1 (5) |
| Time to final culture result (days), median ( | 4 (3–4) |
Note:
Including ascites, bone marrow, joint aspirate (knee), and pleural fluid.
Figure 3Comparison and concordance analysis between shotgun metagenomic sequencing and culture in pathogen detection and drug resistance information.
Comparison and concordance analysis between shotgun metagenomic sequencing and culture in pathogen detection and drug resistance information. (A) The number of positive specimens (y-axis) for pairwise shotgun metagenomic sequencing and culture is plotted against bacterial detection and fungal detection (x-axis) (n = 20). (B, C and D) Pie chart demonstrating the positivity distribution of shotgun metagenomic sequencing and culture for all specimens from bacterial detection (B), fungal detection (C), and antibiotic resistance information (D).
The details of conflicting results between culture and shotgun metagenomic sequencing approach.
| Specimen type | Culture results | Shotgun metagenomic sequencing results | |||
|---|---|---|---|---|---|
| Bacterial results | Fungal results | Species level of bacterial results | Genus level of bacterial results | Fungal results | |
| Ascites | (−) | ||||
| Necrotic tissue | (−) | (−) | |||
| Necrotic tissue | (−) | (−) | (−) | ||
Notes:
Species of highest abundance.
Species listed here are depended on species matching with highest abundance, and most clinical relevance.
The details of conflicting results between antibiotic resistance phenotypes and genotypes by susceptibility testing and shotgun metagenomic sequencing approach.
| No | Resistance information in susceptibility tests | Resistance information in shotgun metagenomic sequencing | ||
|---|---|---|---|---|
| Susceptibility testing results | Antibiotic classes of drugs | Resistance gene types from CARD | Antibiotic classes of genes | |
| P3 | CZO, NIT | Tetracycline, penam, | ||
| P4 | (−) | (−) | Macrolide, lincosamide, streptogramin, sulfonamide, diaminopyrimidine, tetracycline, penam, cephalosporin, glycylcycline, rifamycin, chloramphenicol, fluoroquinolone, monobactam, aminoglycoside | |
| P5 | (−) | (−) | Penam, sulfonamide, diaminopyrimidine, tetracycline, cephalosporin, monobactam, chloramphenicol, fluoroquinolone, macrolide, cephamycin, glycylcycline, rifamycin, aminoglycoside | |
| P9 | AMP, AMC, NIT | Penam, β-lactamase, nitrofuran | Aminoglycoside, macrolide, lincosamide, streptogramin, tetracycline, glycylcycline | |
| P12 | AMK, AMP, AMC, TZP, CRO, FEP, FOX, ATM, IMP, TOB, GEN, CIP, SMZ-TMP, NIT | |||
| P17 | CSL, SAM, CAZ, MEM, AMK, AMP, TZP, AMC, CRO, FEP, FOX, IMP, GEN, TOB, LVX, CIP, SMZ-TMP, NIT | β-lactamase, cephalosporin, penam, | ||
| P18 | CZO, FOX, SMZ-TMP, NIT | Cephalosporin, | Tetracycline, aminoglycoside, streptogramin, | |
| P19 | (−) | (−) | Tetracycline, lincosamide | |
| P20 | (−) | (−) | Tetracycline, lincosamide, macrolide, streptogramin, penam, fluoroquinolone, aminoglycoside | |
Notes:
Only non-susceptibility is listed.
Resistance genes listed here are the top 10 genes with relative abundance higher than 1%.
Reference number cells were highlighted in grey if resistance information of whole metagenome-shotgun sequencing results conflicted with susceptibility tests, where conflicts were defined by when the consistency of the antibiotic classes in susceptibility tests and annotated by CARD database was less than or equal to 50%. Consistent resistant classes between susceptibility tests and resistance genes were shown in bold. AMC, amoxicillin-clavulanic acid; AMK, amikacin; AMP, ampicillin; ATM, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; CSL, cefpoerazone-sulbactam; CTT, cefotetan; CXM, cefuroxime; CZO, cefazolin; ERY, erythromycin; ESBLs, extended spectrum beta-lactamases; ETP, ertapenem; FEP, cefepime; FOX, cefoxitin; GAT, gatifloxacin; GENhl, gentamicin high-level; IMP, imipenem; LVX, levofloxacin; MEM, meropenem; MFX, moxifloxacin; NIT, nitrofurantoin; OXA, oxacillin; PEN, penicillin; PIP, piperacillin; SAM, ampicillin-sulbactam; SMZ-TMP, sulfamethoxazole-trimethoprim; TCY, tetracycline; TOB, tobramycin; TZP, piperacillin-tazobactam.